Abstract Eight-hydroxyquinolines (8HQs) are a class of compounds that have been identified as potential therapeutics for a number of neurodegenerative diseases. Understanding the influence of structural modifications to the 8HQ scaffold on cellular behaviour will aid the identification of compounds that might be effective in treating dementias. In this study, we describe the action of 2-[(dimethylamino)methyl]-8-hydroxyquinoline (DMAMQ) on adult murine neural stem cells (NSCs) cultured in vitro. Treatment of NSCs with DMAMQ resulted in enhanced self-renewal and increased neurite outgrowth. Concurrent with the positive growth effects was an increase in intracellular reactive oxygen species, with the growth being inhibited by inactivation of the NADPH oxidase (Nox) enzyme family. Our results indicate that DMAMQ can stimulate neurogenesis via the Nox signalling pathway, which may provide therapeutic benefit in treating dementias of various types by replenishing neurones using the brain's own reserves. The narrow concentration range over which these effects were observed, however, suggests that there may exist only a small therapeutic window for neuro-regenerative applications.
Introduction
Endogenous neural stem cells (NSCs) are an as-yet untapped resource in combatting dementia. Low levels of NSCs persist in the brain throughout adult life, maintaining the ability to self-replicate and to differentiate into mature brain cells. During dementia, neurogenesis (the ability to form new neurones) is seen to become dysregulated [1, 2] . In rodent models of Alzheimer's disease (AD), production of beta-amyloid, one hallmark of AD, changes the growth and differentiation of these cells [3] [4] [5] [6] [7] . Neurogenesis has been extensively linked with both learning and forgetting [8] [9] [10] ; therefore, changes in these processes might contribute significantly to the cognitive changes that occur during neurodegenerative diseases, including AD. Compounds that modulate or normalise the functions of NSCs represent a prime target for alleviating the symptoms associated with, or delaying the course of, neurodegenerative diseases.
Unbiased chemical screening of substituted 8-hydroxyquinolines (8HQs) and a range of investigations in yeast, nematodes, mice and humans have highlighted the variable mechanisms by which they may act. Side-chain modifications to the 8HQ backbone may lead to functional differences in vivo, with applications of substituted 8HQs as anti-microbial agents [11, 12] , anti-cancer agents [13, 14] , epigenetic modulators [15, 16] , dementia treatments [17] [18] [19] [20] , artificial nucleobases [21] and medical imaging agents [22, 23] . Moreover, biosynthesis of substituted 8HQs has been identified in mammals (e.g. xanthurenic acid [24] ), bacteria (e.g. quinolobactin [25] ) and insects (e.g. 2-carboxy-8HQ [26] ). In dementia applications, studies utilising 5,7-dichloro-2-[(dimethylamino)methyl]-8-hydroxyquinoline reported an increased neurite number following treatment of cultured PC12 cells and a restoration of hippocampal dendritic spine density (but not number) in transgenic mouse model of AD [18] .
In the current study, we sought to further understand the action of this class of 8HQ by treating adult murine NSC cultures with 2-[(dimethylamino)methyl]-8-hydroxyquinoline (DMAMQ; Fig. 1 ). We specifically assessed the ability of these cells to self-renew, essential for maintaining their numbers in the brain throughout life, and to differentiate into new CNS lineage cells. Our findings show that whilst neurogenesis is unchanged, NSCs treated with DMAMQ demonstrate an increase in NSC proliferation and an increased neurite outgrowth during neurogenesis that was signalled by increased production of reactive oxygen species (ROS) signalling intermediates by the NADPH oxidase (Nox) enzyme family. These effects were only observed within a narrow concentration range, suggesting a small therapeutic window for neuro-regenerative applications.
Materials and Methods
Synthesis 2-[(dimethylamino)methyl]-8-hydroxyquinoline (DMAMQ) was synthesised as described previously [27] .
Cell Culture
Murine NSCs were harvested from the brains of 6-8 weekold Balb/c mice and grown without modification as neurospheres in liquid culture as described previously [28] .
DMAMQ Treatments
DMAMQ was included in the culture medium at the concentrations indicated. For all assays, the compound was added as a single treatment at the start of the assay and was not replenished when the media was changed.
Neural Colony Forming Assay (NCFA)
The NCFA has been described previously [29] . For each independent experiment over 50 colonies were measured. As stated above, DMAMQ was included in the matrix once only at the start of the incubation.
Neurite Outgrowth Assay
Neurite outgrowth was measured using a neurite outgrowth staining kit (Merck-Millipore) as per the manufacturer's instructions with the following modifications. One hundred thousand cells per condition were incubated in high FGF (20 ng/mL), no EGF, growth media before seeding 100,000 cells per well insert (1 lm pore size) in differentiation medium with or without test compound. Neurite outgrowth was permitted for 2 days before the assay.
Dichlorofluorescein (DCF) Intracellular ROS Assay
The DCF assay has been described previously [30] . Cells were seeded at a density of 3.6 9 10 4 cells/well 24 h before the start of the assay in poly-D lysine coated 96-well plates. Fluorescence intensity was measured every 5 min for 12 h using a FLUOstar Optima (BMG Labtech) fitted with 490 nm excitation and 520 nm emission filters, and initial rates were calculated using tangents to the curve.
MTS Metabolism Assay
Five microlitre of one solution MTS reagent (Promega) per 100 lL media was added to test and media only background control conditions, and incubated under normal culture conditions for 90 min. Reaction product was quantified using absorbance at 462 nm in a FLUOstar Optima.
b-Galactosidase Staining and Quantification
The cells were stained using a Cell Signalling Technologies' b-galactosidase staining kit as per the manufacturer's instructions. To solubilise the stain for quantitation by spectrometry, the staining solution was removed from the wells and replaced with 350 lL of DMSO. The plate was warmed with agitation at 50°C for 1 h before 100 lL of dissolved dye was transferred to three wells of a 96-well plate for triplicate reads.
Immunofluorescence Staining
The immunofluorescence staining protocol for NSC lineage has been described previously [31] . 
Ki67 Flow Cytometry
Ki67 expression in proliferating cells was quantified using the Muse Ki67 Proliferation Kit (Millipore) as per the manufacturer's instructions. For the final analysis, the number of unstained cells gated as positive was subtracted from the stained cells and the percentage change was calculated from the control cells.
Cell Cycle Phase Flow Cytometry
Cell cycle phase analysis by DNA content was determined using the Muse cell cycle analysis kit (Millipore) as per the manufacturer's instructions.
PAGE and Western Blotting
Polyacrylamide gel electrophoresis and western blotting were conducted as described previously [32] . Primary antibodies and concentrations were as follows; pMEK1, pMEK2 and pGSK-3b (Abcam) 1 in 1000; nestin (Sigma) 1 in 1000; GFAP (Stem Cell Technologies) 1 in 5000; and Neurofilament-L (Invitrogen) 1 in 1000. Relative densitometric comparisons were normalised for total protein loading as shown in Coomassie-stained images.
Calcium Assay
Cells were seeded in 96-well plates as mentioned above. At the beginning of the assay, 50 lL of culture media was removed from each well and replaced with calcium assay working buffer as per manufacturer's instructions (Invitrogen). Plates were incubated for 1 h under normal incubator conditions protected from light before test reagent addition. Readings were taken using 488 nm excitation and 530 nm emission filters in a FluoSTAR Optima (BMG Labtech) every 60 s for 1 h from addition.
Statistical Analyses
Statistical analyses were carried out using GraphPad Prism 5 statistical software. The relevant statistical test applied is indicated in the figure legend. Where significant differences were found, Dunnett, Bonferroni and Dunn's tests were used for multiple comparisons of oneway, two-way and non-parametric ANOVA, respectively. Graphs show the mean and standard error of the mean (SEM) of n independent experiments unless otherwise stated.
Results and Discussion
Herein we investigated the potential for DMAMQ to enhance the regenerative capacity of NSCs cultured in vitro. NSC cultures were established using cells harvested from the sub-ventricular zone of adult wild type Balb/c mice and grown in suspension culture as neurospheres. We first examined the influence of DMAMQ on proliferating neurospheres using a colony forming assay. Cells were exposed to one single treatment included in the media matrix at the start of the assay. Exposure of neurospheres to DMAMQ was observed to have a profound effect on the morphology (Fig. 2a) and volume ( Fig. 2b) of the growing neurospheres. Significant toxicity of DMAMQ was only observed at the highest concentration tested (100 lM; Figure S1 ), whereas NSC growth was stimulated in the low lM concentration range. The observed proliferative effect was due to both the number of new neurospheres/colonies being increased (Fig. 2c ) and the distribution of neurosphere sizes shifting towards larger diameters (Fig. 2d ). Since the greatest proliferative effect was observed at 2.5 lM DMAMQ, this concentration was used for subsequent assays.
To investigate the increased growth further, Ki67, a marker expressed only in actively proliferating cells, was assessed by flow cytometry. An approximate 4 % increase in proliferating cells was seen after 24 h of exposure to DMAMQ in normal culture media (Fig. 3a, b) . Cells that are not proliferating may be quiescent (resting in G0 until stimulated to re-enter the cell cycle) or senescent (an irrecoverable G0 state where cells are unable to re-enter the cell cycle but are not dead). b-galactosidase staining is characteristic of senescent cells. Following 3 days of DMAMQ treatment, administered as a single dose, the number of senescent cells in the culture was decreased by almost 20 % (Fig. 3c) . Analysis of cell cycle phase by DNA content also showed that cells were cycling more rapidly following DMAMQ treatment, with a lower percentage of cells resting in the G0 and G1 phases of the cell cycle following 24 h DMAMQ treatment (Fig. 3d, e) . These results indicate that the observed increase in NSC proliferation was due to a shift towards active proliferation coupled with protection against senescence.
In addition to heightening the ability of NSCs to proliferate in the colony forming assay, we observed a distinct pattern of outgrowth from NSCs cultured in response to DMAMQ suggesting that DMAMQ also promoted neurite outgrowth in the proliferating cultures (Fig. 2a) . To determine whether this was a significant event, the number of neurospheres demonstrating this morphology were counted and showed increased frequency in the DMAMQ-treated colonies (Fig. 3f) . The
ability of DMAMQ to stimulate neurite outgrowth during differentiation was assessed using a colourimetric neurite staining protocol and showed that, over 2 days of differentiation, DMAMQ-treated cells displayed ca. 10 % more neurite outgrowth than was observed for control cells (Fig. 3g) .
To ascertain whether enhanced neurite outgrowth could be linked with enhanced neurogenesis (the capacity to form new neurones), the influence of DMAMQ on neuronal or astrocytic lineage preference following differentiation of NSCs was considered. Lineage commitment of NSCs can be influenced by factors present both when stimulated to differentiate and before they are stimulated to differentiate. Therefore, we considered the effect of including DMAMQ in the culture media during differentiation and also before cells were differentiated as a 'priming' event. For the differentiating culture, DMAMQ was added at the induction of differentiation and remained in the media for 7 days. For the primed culture, NSCs were treated for 24 h prior to differentiation and then transferred into differentiation medium and cultured for 7 days in the absence of further exposure to DMAMQ. Subsequent immunofluorescence staining indicated that DMAMQ incubation did not alter the resulting cell lineages or overtly change the morphology of the differentiated neurones and astrocytes (Fig. 4a) . In addition, western blot analysis (Fig. 4b) confirmed no changes in expression of nestin (Fig. 4c) , neurofilament-L (NF-L; Fig. 4d ) or GFAP (Fig. 2e) either when cells were primed or differentiated with DMAMQ. Therefore, neurogenic potential of NSCs treated with DMAMQ was neither enhanced nor compromised.
Inactivation (by phosphorylation of Ser9) or pharmacological inhibition of GSK-3 leads to both increased proliferation and enhanced neurogenesis in neural stem cell cultures [33, 34] and this phosphorylation has previously been reported in some studies using the 5,7-dichlorinated analogue of DMAMQ [18] ; however, we did not observe any change in the phosphorylation status of GSK-3b following treatment with concentrations of DMAMQ that induced NSC growth (Fig. 5a ). Indeed, a significant increase in phosphorylation was only observed at 100 lM DMAMQ (Figure S2 ), the same concentration at which DMAMQ cytotoxicity was significant ( Figure S1 ). Therefore, signalling through GSK-3b is unlikely to be of relevance to DMAMQ-stimulated NSC growth. Additionally, no detectable changes in AKT and MEK1/2 phosphorylation were observed (Fig. 5a ), indicating these redox-sensitive signalling pathways were not involved in the induction of cell growth.
Many neuronal signalling processes involve calcium flux, and stem cells utilise these pathways [35] . Changes in calcium mobilisation are also linked with redox signalling [36] and increased cytosolic Ca 2? can directly activate some Nox enzymes [37] . Therefore, intracellular calcium levels were measured in the NSCs. Following DMAMQ treatment, a reduction in intracellular calcium was detected (Fig. 5b) .
Redox signalling pathways have been linked with NSC growth and an increased ROS burst has been linked with induction of proliferation [38] [39] [40] . A 'cellular redox cycle' has been shown to occur within the cell cycle and is thought to control cycle phase progression [41, 42] . Measurement of intracellular ROS production using the NSC proliferation [43] [44] [45] . To examine the role of Nox signalling in the ROS produced in response to DMAMQ, a Nox isozyme inhibitor (DPI) was co-administered with DMAMQ in the DCFDA assay. Inclusion of DPI was sufficient to block the DMAMQ-induced ROS response in the NSCs (Fig. 6b) , implicating Nox in the observed intracellular ROS burst. If the ROS produced by the addition of DMAMQ to the cells was signalling the increased growth of the cells, then inhibition of this pathway with DPI would be expected to inhibit the increased colony growth in the NCFA. DPI was included in the media matrix as a single dose at the start of the NCFA with or without NNAMQ and growth was determined as described previously. DPI alone reduced colony growth, primarily affecting the number of colonies formed (Fig. 7a-c) . When DPI and DMAMQ were co-incubated in the media matrix (single treatment at the start of the assay), the growth of the spheres was stunted with fewer colonies formed (Fig. 7a-c) and decreased the diameter at the 2.5 lM treatment concentrations of DMAMQ.
Whilst our results concur with previous literature that increased ROS increases NSC growth and suggest that modulation of Nox to increase ROS signalling initiates such growth, the data presented cannot exclude intrinsic ROS production by DMAMQ that mimics, but does not outcompete inhibition of, this pathway. In any case, the generation of ROS in response to DMAMQ treatment contrasts with the mainstream view that 8HQs can be of therapeutic benefit by reducing aberrant metal-mediated ROS production associated with neurodegenerative disease [46] .
The identification of compounds that regulate neurogenesis holds great promise for treating neurodegenerative conditions. AD-associated Ab peptides have been shown to decrease neurogenesis using both in vivo and in vitro models, including murine NSC cultures [3, 47, 48] and hence, restoration of NSC function by 8HQs could be of value in treating AD. The picture is far from clear, however, because markers of increased neurogenesis can be found in post-mortem analysis of AD brains [2] and also in some animal models of disease [4, 49] . Increased neurogenesis may represent a compensatory response by the NSCs within the brain to replenish lost neurones. In such a context, the current findings suggest that compounds that stimulate neurogenesis during AD may be able to augment these compensatory mechanisms. The caveat, however, is that neurogenesis has also been linked with forgetting [8] ; in theory, stimulating neurogenesis may therefore inadvertently exacerbate the symptoms of memory loss. In addition to these complications, which may arise even from a targeted stimulation of neurogenesis, Nox signalling regulates diverse processes in vivo such as contractile functions of heart muscle [50, 51] and systemic immune responses [37, 52] , whilst acute and chronic Nox activity is associated with neuroinflammation [53] . Moreover, substituted 8HQs can have anti-proliferative/cytotoxic properties depending on their local concentrations ( Figure S1 ) [13] [14] [15] or have the potential to cause neuronal damage by interfering with epigenetic regulation (e.g. clioquinol [54] ). Some of these considerations may explain why clioquinol and 5,7-dichoro-DMAMQ have not shown evidence of clinical benefit in treating AD [55] .
Conclusions
This study demonstrates that DMAMQ modulates NSC growth and neurite outgrowth during differentiation when cultured in vitro by stimulating ROS production and Nox signalling. This suggests that DMAMQ and similar 8HQs may have neuro-regenerative potential in vivo; however, the very narrow concentration range in which DMAMQ modulates NSC growth presents some challenges for therapeutic administration. In particular, the potential benefits of replenishing damaged brain tissue must be balanced against the possibility of overstimulating neurogenesis and the propensity for undesirable ''off-target'' effects. A substantial increase in our understanding of the action of substituted 8HQs in vitro and in vivo is required to determine whether this class of compound will be a viable therapeutic intervention in countering disease progression in any dementia.
